ICON Enhances Endpoint Adjudication Services Using AG Mednet Advanced Technology
June 11 2018 - 7:00AM
Business Wire
ICON plc (NASDAQ: ICLR), a global provider of drug development
and commercialisation solutions and services, today announced it
has signed an agreement with AG Mednet to use Judi, a comprehensive
electronic endpoint adjudication system to manage workflow and
ensure data quality, for enhanced endpoint event adjudication
services. Judi, an integrated, cloud-based SaaS tool, provides a
level of flexibility that enables the implementation of the most
complex endpoint and adverse event processes, delivering fewer
queries, higher transparency and increased quality for clients.
ICON is a leader in endpoint adjudication and has already
successfully deployed Judi for thousands of events across multiple
therapeutic areas including oncology, obesity and diabetes. It has
established relationships with over 400 experts and key opinion
leaders around the world and works collegially with multiple
partners and Academic Research Organizations in support of Data
Monitoring Committees and event adjudication.
“Judi provides a purpose built solution for endpoint
adjudication that enables efficient database set-up, data
extraction and manages workflow effectively,” said Craig McLendon,
Senior Director, Adjudication and Data Monitoring Committees
Management, ICON. “Combining ICON’s adjudication experience and
expertise with innovative technology from AG Mednet enables us
provide a world class service for even the most demanding endpoint
adjudication projects”.
“We developed Judi from the ground up, incorporating a level of
flexibility that enables quality and accuracy in reported data from
studies. ICON has been an ideal partner in ensuring that both the
development and the implementation of Judi meet the technical and
clinical needs of investigator sites, CRO reviewers, adjudicators
and clinical event committees,” said Abraham Gutman, president and
CEO, AG Mednet.
ICON provides customised, efficient, stream-lined, high-quality,
regulatory compliant solutions for projects of all sizes and all
therapeutic areas.
About ICON plcICON plc is a global provider of outsourced
drug development and commercialisation solutions and services to
pharmaceutical, biotechnology, medical device, and government and
public health organisations. The company specializes in the
strategic development, management and analysis of programs that
support clinical development from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON
currently, operates from 97 locations in 38 countries and has
approximately 13,380 employees. Further information is available at
www.iconplc.com/eas
About AG MednetAG Mednet is the leading quality
compliance partner for image data submission and collection, as
well as endpoint adjudication and adverse event adjudication
workflows. The company is a leading proponent of zero-delay
clinical trials, and has supported more than 1,000 global clinical
trials. Dozens of adjudication protocols are managed by sponsors
and CROs using Judi. More than 55,000 registered users across
thousands of investigator sites in more than 80 countries use AG
Mednet to submit more than 14,000,000 images per month and
adjudicate hundreds of events in projects sponsored by each of the
world’s top 20 pharmaceutical, biotech and medical device
companies.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180611005430/en/
Weber ShandwickOlivia Pimenta44-207 067
0557OPimenta@webershandwick.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Apr 2023 to Apr 2024